pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,093 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT824Endpoints622BioPharma Dive237onclive165Fierce Biotech90BioSpace87raps32globenewswire health28fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • Fauci adviser David Morens indicted on charges of concealing emails, avoiding records requests
    The charges against Morens come after Congressional probes related to the origins of the virus that causes Covid-19.
    STAT · 3mo ago↗ source
  • Pfizer deals extend patent life for a top-selling rare disease drug
    Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
    BioPharma Dive · 3mo ago↗ source
  • Boehringer dual-acting obesity shot hits mark in Phase 3 trial
    Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.
    BioPharma Dive
← prev
page 42 of 44
next →
21
fda recalls20
fda medwatch17
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 3mo ago
↗ source
  • STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access
    The Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny labels, with implications for the availability of generics.
    STAT · 3mo ago↗ source
  • FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
    Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.
    BioPharma Dive · 3mo ago↗ source
  • STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
    Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
    STAT · 3mo ago↗ source
  • STAT+: Google’s clinical director on AI challenges
    In this edition of STAT Health Tech newsletter: a conversation with Google's clinical director, an update on Doctronic's Utah experiment, and more.
    STAT · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
    The Novartis CEO warned that Trump's drug pricing policy poses a “very difficult situation” and the reality will soon catch up with drugmakers and patients
    STAT · 3mo ago↗ source
  • Coultreon banks $125M to support testing of former Galapagos immune drug
    Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.
    BioPharma Dive · 3mo ago↗ source
  • Predicting consequences of new hepatitis B vaccine recs
    New data on public trust in science, AI and mental health, and other news from Morning Rounds
    STAT · 3mo ago↗ source
  • Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
    Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
    BioPharma Dive · 3mo ago↗ source
  • STAT+: Eli Lilly enlists AI startup for next-generation gene editors
    Eli Lilly's deal with Profluent aims to go beyond CRISPR by using AI-designed enzymes to insert entire genes. It could reshape genetic medicine.
    STAT · 3mo ago↗ source
  • Opinion: It’s time to seize the rare bipartisan opening to address microplastics
    “This could be the start of serious action on microplastics. Or it could end up as a headline with little behind it,” write Tim Ryan and Justin Zorn.
    STAT · 3mo ago↗ source
  • Opinion: Why do discussions about ‘brain health’ ignore mental illness?
    “Failing to adopt a more inclusive concept of brain health represents a massive loss of human potential,” write Husseini K. Manji, Eric J. Nestler, and Patrick J. Kennedy.
    STAT · 3mo ago↗ source
  • STAT+: A giant question looms over GOP’s new Medicaid work requirements
    Coverage losses tied to Medicaid work requirements may not be tracked in every states.
    STAT · 3mo ago↗ source
  • STAT+: Google clinical director says AI can be a ‘bridge’ for people having a mental health crisis
    Google's clinical director Megan Bell Jones on how the company is addressing concerns over mental health impacts of its AI products.
    STAT · 3mo ago↗ source
  • New U.S. recommendation on hepatitis B vaccine will have dire consequences, studies project
    Policy that recommends offering hep B vaccine at birth only to babies perceived to be at risk will lead to increased numbers of infected infants, new studies project.
    STAT · 3mo ago↗ source
  • Supreme Court grapples with multibillion-dollar wave of lawsuits over Roundup cancer claims
    The Supreme Court seemed divided Monday over whether to block thousands of lawsuits alleging the maker of the weedkiller Roundup failed to warn people it could cause cancer.
    STAT · 3mo ago↗ source
  • STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy
    The drugmaker Erasca said results on its experimental pill in a trial of pancreatic cancer and non-small cell lung cancer exceeded its expectations.
    STAT · 3mo ago↗ source
  • STAT+: Dems say RFK Jr. has a pattern of failing to answer their questions
    Kennedy broke his pledge to share a controversial contract, highlighting Democrats' frustrations with the health secretary.
    STAT · 3mo ago↗ source
  • Trump administration warns against using federal dollars on fentanyl test strips
    The Trump administration underlines a “clear shift away from harm reduction and practices” that it says facilitates illegal drug use.
    STAT · 3mo ago↗ source
  • Oruka surges as long-acting psoriasis drug shows early promise
    A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
    BioPharma Dive · 3mo ago↗ source
  • Veradermics soars on positive data for baldness treatment
    The results could support the first approval in decades for an oral medicine that can treat male pattern baldness, though the therapy will face competition from generics and over-the-counter medica…
    BioPharma Dive · 3mo ago↗ source
  • STAT+: An insider reveals the real goals of prior authorization
    Years ago, Archelle Georgiou helped squash prior auths at one of America's biggest health insurers.
    STAT · 3mo ago↗ source
  • Lilly to buy startup Ajax in bid for a better JAK drug
    Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.
    BioPharma Dive · 3mo ago↗ source